Table 2.
Clinical variables at baseline and after 12 weeks treatment in JLD and control groups
| Variables | JLD group (n = 32) | Control group (n = 29) | After 12 weeks treatment, JLD group versus control group | |||
|---|---|---|---|---|---|---|
| Baseline | After 12 weeks | Baseline | After 12 weeks | Statistical values | P | |
| FPG (mmol/L) | 6.2 ± 0.5 | 5.8 ± 0.6* | 6.3 ± 0.55 | 6.0 ± 0.6* | 1.874‡ | 0.176 |
| 2-h PG (mmol/L) | 8.5 ± 2.1 | 7.7 ± 2.0† | 9.4 ± 1.6 | 10.3 ± 2.5 | 14.425‡ | <0.001 |
| HbA1c (%) | 6.5 ± 0.7 | 6.0 ± 0.6* | 6.5 ± 0.5 | 6.5 ± 0.5 | 23.340‡ | <0.001 |
| Fasting insulin (μU/ml) | 9.2 (7.0, 15.3) | 9.5 (6.5, 11.9)† | 9.0 (8.1, 10.7) | 11.4 (8.3, 12.4)* | –1.813§ | 0.070 |
| HOMA-IR | 2.4 (2.0, 4.0) | 2.41 (1.7, 3.9)† | 2.5 (2.1, 3.0) | 3.0 (2.1, 3.3)* | –2.181§ | 0.029 |
| Weight (kg) | 61.7 ± 9.0 | 60.2 ± 9.6* | 62.7 ± 8.2 | 61.1 ± 7.6* | 0.005‡ | 0.944 |
| BMI (kg/m2) | 22.9 ± 2.5 | 22.3 ± 2.4* | 23.6 ± 2.7 | 23.0 ± 2.2* | 0.271‡ | 0.605 |
| Waist (cm) | 83.4 ± 9.1 | 82.6 ± 9.4† | 81.5 ± 5.4 | 80.9 ± 4.5 | 0.002‡ | 0.965 |
| Waist/hip ratio | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.1 | 0.9 ± 0.0 | 0.135‡ | 0.715 |
| Triglycerides (mg/L) | 15.3 ± 7.8 | 15.0 ± 7.1 | 15.4 ± 7.9 | 13.4 ± 5.4 | 3.289‡ | 0.075 |
| Total cholesterol (mg/L) | 56.1 ± 10.5 | 52.4 ± 10.1* | 55.5 ± 9.1 | 49.7 ± 5.6* | 2.362‡ | 0.130 |
| HDL-C (mg/L) | 13.5 ± 3.1 | 13.1 ± 2.7 | 14.2 ± 2.7 | 13.3 ± 2.4† | 0.268‡ | 0.606 |
| LDL-C (mg/L) | 33.8 ± 6.2 | 32.6 ± 6.1 | 32.4 ± 8.3 | 31.2 ± 5.9 | 0.267‡ | 0.607 |
Data are shown as mean ± SD, or median (Q1, Q3). *P<0.01, †P<0.05, compared with baseline in the same group using paired t-test or Wilcoxon test. ‡Analysis of covariance; §Mann-Whitney’s U-test. BMI: Body mass index; FPG: Fasting plasma glucose; 2-h PG: 2-h plasma glucose; HbA1c: Glycated hemoglobin A1c; HOMA-IR: Insulin resistance index of homeostasis model assessment; HDL: High-density lipoprotein cholesterol; LDL: Low-density lipoprotein cholesterol; JLD: Jinlida; SD: Standard deviation.